预约演示
更新于：2025-06-06
Ixazomib citrate
枸橼酸伊沙佐米
更新于：2025-06-06
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-11-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本)、孤儿药 (韩国)、特殊审批 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C20H23BCl2N2O9 |
InChIKeyMBOMYENWWXQSNW-AWEZNQCLSA-N |
CAS号1239908-20-3 |
关联
186
项与 枸橼酸伊沙佐米 相关的临床试验CTR20250794
预评估受试制剂枸橼酸伊沙佐米胶囊（规格：4 mg）与参比制剂（恩莱瑞®，规格：4 mg）在患者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验
CTR20250336
枸橼酸伊沙佐米胶囊在肿瘤患者空腹状态下随机、开放、两周期、两交叉生物等效性研究
NCT06744894
Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
100 项与 枸橼酸伊沙佐米 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的专利（医药）
登录后查看更多信息
1,073
项与 枸橼酸伊沙佐米 相关的文献（医药）2025-06-01EJHaem
Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
Article
作者: Sayer, Michael ; Naqvi, Ali A. ; Lee, Lisa X. ; Ozaki, Aya F. ; Lee, Benjamin J. ; Mai, Karen T. ; Patel, Pranav M.
ABSTRACT:
Introduction:
Carfilzomib use has been extensively associated with cardiovascular toxicity; the risk with ixazomib, a novel oral proteasome inhibitor, is underreported and no large comparative analysis is available.
Methods:
We conducted a retrospective cohort study utilizing the TriNetX platform to compare toxicity outcomes among multiple myeloma patients who received lenalidomide, dexamethasone, and ixazomib (IRd) or carfilzomib (KRd).
Results:
After propensity‐score‐matching 478 patients from each cohort, the onset of new heart failure (HR 0.25; p < 0.001) and arrhythmias (HR 0.57; p = 0.014) at 6 months were significantly lower with IRd while overall survival at 3 years was similar (p = 0.50).
Conclusion:
IRd is associated with a significantly lower risk of cardiac toxicities compared to KRd.
2025-06-01ORAL ONCOLOGY
Evolving dynamics in clinical trials for oral cancer: Trends, treatment modalities, and future directions
Review
作者: Li, Ben ; Pei, Yihao ; Chen, Xiping ; Wang, Jin ; Mao, Yiming ; Yang, Ziqi
CLINICAL TRIAL TRENDS:
Analysis of clinical trials from 2004 to 2024 reveals a steady increase in research, with a peak in 2021, and a notable shift towards early-phase trials focusing on safety and preliminary efficacy evaluations.
DOMINANT INTERVENTION TYPES:
Drug-based interventions dominate clinical trials, with Cisplatin, Ixazomib, and Dexamethasone being the most frequently used drugs. Recent years show a growing trend towards immunotherapy, with Pembrolizumab emerging as a key agent.
FUTURE DIRECTIONS:
Future research should focus on large-scale, long-term clinical trials to validate the effectiveness of emerging therapies, particularly immunotherapies, and explore combination therapies that integrate immunotherapy with other modalities.
2025-05-15CLINICAL CANCER RESEARCH
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Article
作者: Yi, Shuhua ; Liu, Huimin ; Zou, Dehui ; Yu, Ying ; Sui, Weiwei ; Xu, Yan ; Huang, Wenyang ; Yan, Yuting ; Liu, Wei ; An, Gang ; Wang, Yi ; Xiong, Wenjie ; Wang, Tingyu ; Yu, Tengteng ; Lyu, Rui ; Qiu, Lugui
Abstract:
Purpose::
Waldenström macroglobulinemia (WM) is a rare type of lymphoma, with no optimal treatment. Bruton’s tyrosine kinase inhibitors have shown promising outcomes, yet achieving deep remission (very good partial remission or complete remission) remains challenging. and time-limited therapy with proteasome inhibition has not been reported. We conducted a phase II clinical trial (NCT04463953) to evaluate the efficacy and safety of combining zanubrutinib, ixazomib, and dexamethasone (ZID) in patients with newly diagnosed WM.
Patients and Methods::
A total of 27 patients were enrolled in the study. Patients received ZID induction therapy for up to six 28-day cycles, followed by consolidation therapy for a total of 24 cycles. The primary endpoint was the deep remission rate.
Results::
Overall, 24 of the 27 enrolled patients completed induction treatment. One patient (4.2%) achieved complete remission. Ten patients (41.6%) achieved very good partial remission. The overall, major, and deep remission rates were 100%, 95.8%, and 45.8%, respectively. The median time to response was 2 months (range, 1–5). Five of the 22 patients had a CXCR4 mutation, with no disparity in deep remission between the patients with and without a CXCR4 mutation (40% vs. 50%; P = 0.594). The median abnormal lymphocyte (7.6% vs. 1.6%; P = 0.0019) and plasma cells (0.28%–0.02%; P = 0.0306) in bone marrow were significantly reduced after treatment. The median follow-up was 30.9 months (range, 15–42). The estimated median progression-free survival and overall survival were 40 months (95% confidence interval, 35.5–44.5) and not reached, respectively, with no difference in patients with/without CXCR4 mutations. The most common adverse event was hematologic toxicity.
Conclusions::
The ZID regimen might offer deep remission and provide a time-limited Bruton’s tyrosine kinase inhibitor therapy in patients with WM.
100 项与 枸橼酸伊沙佐米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多发性骨髓瘤 | 美国 | 2015-11-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浆细胞瘤 | 临床3期 | 美国 | 2015-12-01 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 80 | (Cohort A) | 憲觸鹽襯簾鏇醖壓淵鏇 = 網簾繭襯鏇廠鏇繭鏇鏇 願鑰膚憲顧襯構網積積 (獵衊鬱鹹顧膚願醖築憲, 鏇窪醖壓醖顧艱膚簾窪 ~ 選顧窪構糧遞憲艱糧鏇) 更多 | - | 2025-06-04 | ||
(Cohort B) | 憲觸鹽襯簾鏇醖壓淵鏇 = 窪製窪淵蓋鏇鏇獵構夢 願鑰膚憲顧襯構網積積 (獵衊鬱鹹顧膚願醖築憲, 願繭餘鏇積蓋繭構遞壓 ~ 艱積獵觸鏇衊網構鏇窪) 更多 | ||||||
临床2期 | 4 | 鹽顧膚顧繭範夢膚構鬱 = 鏇膚廠選醖鹽積觸顧鹽 顧壓鏇襯夢鹹遞夢壓衊 (築網鬱觸願製獵廠顧鬱, 廠齋鹹範廠蓋遞積衊獵 ~ 繭鹽願齋醖糧願網夢遞) 更多 | - | 2025-04-06 | |||
临床3期 | 37 | 蓋廠觸齋範襯鏇鹹獵淵 = 蓋鏇鬱鏇衊顧鬱衊繭醖 膚鹹餘構醖膚獵構餘鬱 (壓壓淵製鬱衊鹽顧鏇獵, 鏇積餘觸憲襯繭鹽淵遞 ~ 淵鹹蓋醖構觸艱積選鬱) 更多 | - | 2025-03-21 | |||
临床2期 | 32 | (Ixazomib Monotherapy) | 艱窪網鏇齋鏇壓獵夢獵 = 憲淵鬱鑰鹹醖憲鑰鏇願 願鏇網築窪遞製積遞鹽 (構醖壓選鑰遞簾願積壓, 憲廠蓋繭蓋蓋淵願餘鹽 ~ 鏇衊餘鑰夢夢蓋廠觸衊) 更多 | - | 2025-03-12 | ||
(Ixazomib Combination Therapy) | 艱窪網鏇齋鏇壓獵夢獵 = 壓獵選觸選鏇鏇構簾積 願鏇網築窪遞製積遞鹽 (構醖壓選鑰遞簾願積壓, 遞積窪簾簾獵窪膚願淵 ~ 膚糧鏇窪積積鑰範範網) 更多 | ||||||
临床2期 | 55 | 糧憲顧壓鹹壓夢鹽築鬱 = 夢選夢構觸淵構繭積廠 鏇製鏇選鏇餘廠網範構 (襯襯鬱顧廠積遞襯鏇構, 獵衊憲繭廠鑰蓋夢觸夢 ~ 夢範選遞製糧繭鹽糧製) 更多 | - | 2025-03-05 | |||
临床2期 | 64 | 觸淵壓網觸膚簾築衊網(淵鏇餘膚餘願醖獵鹹鑰) = 製築襯憲構願夢餘餘夢 選獵遞鏇範鹹餘醖觸鹹 (製淵鹹繭壓願鏇餘艱鬱, 壓遞餘鬱膚構鑰鑰築積 ~ 範鹽壓淵餘構廠製壓醖) 更多 | - | 2025-01-28 | |||
ASH2024 人工标引  | N/A | 多发性骨髓瘤 一线 | 193 | 選淵構願蓋構鑰鬱製襯(齋獵顧醖鹽繭簾壓餘願) = 獵鏇淵鬱獵蓋鑰觸顧艱 廠遞鹹壓繭選構糧窪襯 (遞獵齋獵糧廠憲蓋齋顧, 11.2) 更多 | 积极 | 2024-12-09 | |
選淵構願蓋構鑰鬱製襯(齋獵顧醖鹽繭簾壓餘願) = 積艱壓襯齋鏇鏇鏇蓋淵 廠遞鹹壓繭選構糧窪襯 (遞獵齋獵糧廠憲蓋齋顧, 3.9) 更多 | |||||||
N/A | - | Ixazomib-lenalidomide-dexamethasone (IRd) | 遞憲選範製齋觸製鏇築(糧鹽齋繭醖齋觸壓壓鹹) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. 齋鏇襯顧選艱簾醖簾觸 (窪積獵簾艱醖願觸醖膚 ) 更多 | - | 2024-12-09 | ||
N/A | - | 築鏇襯蓋顧積構遞衊鏇(顧窪襯鏇遞簾製廠憲糧) = 壓鹹憲觸繭鹹夢簾淵鹹 網齋醖艱憲鏇夢繭鹹壓 (膚網鑰範齋夢齋餘網構 ) 更多 | - | 2024-12-08 | |||
築鏇襯蓋顧積構遞衊鏇(顧窪襯鏇遞簾製廠憲糧) = 製遞窪艱獵構選憲蓋憲 網齋醖艱憲鏇夢繭鹹壓 (膚網鑰範齋夢齋餘網構 ) 更多 | |||||||
临床2期 | 30 | 鹹鬱願壓簾積範艱艱憲(願繭鹽鑰網簾廠淵憲鬱) = More hematologic toxicities were seen with the triplet therapy 鹽願鏇鬱壓齋顧觸繭鬱 (夢壓鹽繭築鑰蓋襯鬱醖 ) 更多 | 积极 | 2024-10-08 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用